Clinical Trial Update: Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

terminated Phase 1/2 trial evaluating ide-cabtagene vicleucel (bb2121) combinations in multiple myeloma, reporting on safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Abecma (idecabtagene vicleucel)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED